reported that ATM mutations significantly increase immune activity in MSS colon adenocarcinoma (COAD) patients, supporting the feasibility of using ATM mutation status as a predictor of the immunotherapy response in MSS COAD (24). Here, ATM is linked to colon adenocarcinoma.